Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The ODYSSEY COMBO I study (http://clinicaltrials.gov/show/NCT01644175) evaluated efficacy and safety of alirocumab as add-on therapy to stable maximally tolerated daily statin with or without other lipid-lowering therapy in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am. Heart J.

Title: American heart journal

ISSN (Electronic): 1097-6744

ISSN (Print): 0002-8703

Publication date (Electronic): Jun 2015

Volume: 169

Issue: 6

Affiliations

[1 ] The Christ Hospital, Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH. Electronic address: Lindner@thechristhospital.com.

[2 ] University of Iowa, Iowa City, IA.

[3 ] Harvard Clinical Research Institute, Boston, MA.

[4 ] Sanofi, Chilly-Mazarin, France.

[5 ] Regeneron Pharmaceuticals, Inc, Tarrytown, NY.

[6 ] Sanofi, Bridgewater, NJ.

[7 ] University of Dundee, Dundee, Scotland, United Kingdom.

Article

Publisher Item ID: S0002-8703(15)00168-4

DOI: 10.1016/j.ahj.2015.03.004

PubMed ID: 26027630

SO-VID: f9c256ed-2a82-4056-b199-9a2ab109a765

History

Data availability:

Comments

Comment on this article

scite_

Cited by 108

See all cited by

- Version 1